Matthew D Disney Selected Research

Myotonic Dystrophy (Dystrophia Myotonica)

1/2021	A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways.
11/2020	Macrocyclization of a Ligand Targeting a Toxic RNA Dramatically Improves Potency.
1/2020	Optimization of the Linker Domain in a Dimeric Compound that Degrades an r(CUG) Repeat Expansion in Cells.
1/2020	Precise Targeted Cleavage of a r(CUG) Repeat Expansion in Cells by Using a Small-Molecule-Deglycobleomycin Conjugate.
1/2020	Structure-Specific Cleavage of an RNA Repeat Expansion with a Dimeric Small Molecule Is Advantageous over Sequence-Specific Recognition by an Oligonucleotide.
1/2020	A Toxic RNA Templates the Synthesis of Its Own Fluorogenic Inhibitor by Using a Bio-orthogonal Tetrazine Ligation in Cells and Tissues.
1/2020	A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.
1/2019	Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
11/2017	Structure and Dynamics of RNA Repeat Expansions That Cause Huntington's Disease and Myotonic Dystrophy Type 1.
1/2017	Precise small-molecule recognition of a toxic CUG RNA repeat expansion.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew D Disney Research Topics

Disease

26	Myotonic Dystrophy (Dystrophia Myotonica) 01/2021 - 05/2009
11	Neoplasms (Cancer) 01/2020 - 04/2014
7	Fragile X Tremor Ataxia Syndrome 12/2021 - 10/2012
6	Triple Negative Breast Neoplasms 01/2022 - 01/2017
6	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2015
5	Muscular Dystrophies (Muscular Dystrophy) 01/2020 - 07/2009
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 03/2017
4	Frontotemporal Dementia (Semantic Dementia) 10/2021 - 09/2014
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 10/2021 - 01/2017
3	Parkinsonian Disorders (Parkinsonism) 01/2020 - 09/2014
3	Hypoxia (Hypoxemia) 01/2019 - 10/2015
2	Disease Progression 01/2021 - 01/2020
2	Huntington Disease (Huntington's Disease) 01/2020 - 11/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 03/2013
2	Neuromuscular Diseases (Neuromuscular Disease) 01/2020 - 04/2014
2	Nervous System Diseases (Neurological Disorders) 01/2020 - 07/2015
2	Spinocerebellar Ataxia 10 01/2016 - 06/2015
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 01/2016 - 06/2015
2	Myotonic Disorders (Paramyotonia Congenita) 02/2011 - 02/2010
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Hereditary Nephritis (Alport Syndrome) 01/2021
1	COVID-19 10/2020
1	Heart Failure 10/2020
1	Parkinson Disease (Parkinson's Disease) 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2020
1	Neoplasm Metastasis (Metastasis) 01/2020
1	TDP-43 Proteinopathies 01/2019
1	Dehydration (Water Stress) 11/2016
1	Hepatocellular Carcinoma (Hepatoma) 02/2016
1	Hepatic Encephalopathy 02/2016
1	Bacterial Infections (Bacterial Infection) 02/2016
1	Fibrosis (Cirrhosis) 02/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2016
1	Fragile X Syndrome (Martin Bell Syndrome) 02/2014
1	Machado-Joseph Disease (Spinocerebellar Ataxia Type 3) 07/2009
1	Body Weight (Weight, Body) 04/2005

Drug/Important Bio-Agent (IBA)

41	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2009
14	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2009
11	RNA Precursors (Precursor, mRNA)IBA 01/2020 - 10/2012
7	LigandsIBA 01/2022 - 05/2009
6	MicroRNAs (MicroRNA)IBA 01/2022 - 03/2013
3	Protein Kinases (Protein Kinase)IBA 01/2020 - 03/2012
3	Untranslated RNA (Noncoding RNA)IBA 01/2019 - 01/2018
3	Messenger RNA (mRNA)IBA 09/2014 - 05/2012
3	NucleotidesIBA 02/2014 - 12/2009
2	Alkynes (Acetylenes)IBA 01/2022 - 10/2014
2	Carrier Proteins (Binding Protein)IBA 01/2020 - 01/2020
2	Ribonucleases (Ribonuclease)IBA 01/2020 - 01/2018
2	3' Untranslated Regions (3' UTR)IBA 01/2020 - 05/2012
2	Nucleic AcidsIBA 01/2020 - 01/2020
2	bleomycetinIBA 01/2020 - 11/2018
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2020 - 10/2019
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 05/2016 - 12/2015
2	OligonucleotidesIBA 01/2016 - 04/2014
2	5' Untranslated Regions (5' UTR)IBA 04/2015 - 03/2013
1	rat MIRN27 microRNAIBA 01/2022
1	DiazomethaneIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020
1	SynucleinsIBA 01/2020
1	ProteomeIBA 01/2020
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020
1	Protein AggregatesIBA 01/2020
1	cugamycinIBA 01/2020
1	tau Proteins (tau Protein)IBA 10/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	Ado-Trastuzumab EmtansineIBA 01/2019
1	Trastuzumab (Herceptin)FDA Link 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 11/2018
1	AminesIBA 11/2018
1	8-hydroxyguanosineIBA 01/2018
1	GuanosineIBA 01/2018
1	2-5A-dependent ribonuclease (RNase L)IBA 01/2018
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 03/2017
1	EnzymesIBA 01/2017
1	Glycerolphosphate Dehydrogenase (Glycerol 3 Phosphate Dehydrogenase)IBA 01/2017
1	targaprimir-96IBA 05/2016
1	Framycetin (Framycetin Sulfate)IBA 02/2016
1	Caspase 3 (Caspase-3)IBA 01/2016
1	Initiator Codon (Start Codon)IBA 01/2016
1	Fluorouracil (Carac)FDA LinkGeneric 10/2015
1	TOR Serine-Threonine KinasesIBA 10/2015
1	AntagomirsIBA 10/2015
1	AzidesIBA 10/2014
1	AminoglycosidesIBA 12/2012
1	Bisbenzimidazole (Hoechst 33258)IBA 04/2005

Therapy/Procedure

5	Therapeutics 12/2021 - 07/2015
1	Ligation 01/2020
1	Precision Medicine 01/2019
1	Surgical Instruments (Clip) 05/2016